ASC Therapeutics
Company Type: Therapeutic development
Main focus: Developing curative treatments for various diseases through a proprietary gene-editing platform, TARGATT™, and other gene-editing technologies
Company stage: Clinical
Diseases: β-Thalassemia, haemophilia, and graft-versus-host disease
Genome-editing tool: CRISPR-Cas9 and TARGATT™
Funding stage: Private
Location: Milpitas, California, USA
Website: https://www.asctherapeutics.com/
Pipeline: https://www.asctherapeutics.com/our-pipeline/
Partners: University of Massachusetts, University of Pennsylvania, Stanford University, Emory University, Shantou University, Peking University Shenzhen Hospital
ASC Therapeutics is a biotechnology company focused on developing gene therapies for rare genetic disorders. The company uses advanced CRISPR gene editing and gene replacement technologies to create treatments for diseases such as haemophilia A and B, β-thalassemia, and other monogenic conditions. ASC Therapeutics has so far disclosed three pre-clinical-stage gene-editing programmes.